Navigation Links
INVO Bioscience Announces First Shipments of INVOcell Into Bolivia
Date:12/21/2010

effective solution to this very unfortunate problem."

INVOcell is registered as a class II device in Bolivia, and therefore according to local laws does not require extended registration. The company continues to market its products in all applicable countries covered by CE Mark or other local accepted criteria.  Additionally, the company has commenced registration processes in China and Ukraine, while continuing to explore additional appropriate countries to begin the registration process to market its products.

INVOcell is CE Mark approved in Europe and Canada and conforms with all consumer health and safety requirements. INVOcell is currently marketed and sold in Austria, Bolivia, Cameroon, Columbia, the Dominican Republic, Guatemala, Nicaragua, Pakistan, Panama, Peru, Spain, Togo, Turkey, and Venezuela.

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.

Private Securities Litigation Reform Act of 1995

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and servic
'/>"/>

SOURCE INVO Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ambit Biosciences Initiates Two Phase I Clinical Trials
2. Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
3. Cell Biosciences Announces US Patent Issuance
4. Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
5. ChromaDex Partners With Kappa Bioscience to Provide Quality Control Methods, Tools and Services for Vitamin K2
6. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
7. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
8. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
9. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
11. Magellan Biosciences to Debut Revolutionary New Dynex® Clinical Diagnostics Processing System for Fully Automated ELISA Testing at MEDICA 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014 Capnia, Inc. (NASDAQ: ... of medical diagnostics based on its proprietary Sensalyze™ ... today announced financial results for the third quarter ... "Following the completion of our initial public ... maximize the recently initiated CoSense® commercial launch," said ...
(Date:12/19/2014)... 2014   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... from its pivotal field study of AT-001 (Grapiprant), ... dogs with osteoarthritis.  In the study, dogs receiving ... were statistically significant compared to placebo (p<0.05) at ...
(Date:12/17/2014)... 2014 Los beneficios y ganancias ... nivel de gasto en investigación y desarrollo   ... 30 de septiembre de 2014) ZEISS aumentó sus ingresos ... euros (año anterior: 4.190 millones de euros) a pesar ... (EBIT) crecieron un 14 por ciento, a 360 millones ...
Breaking Medicine Technology:Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS confirma su posición en un entorno difícil 2
... Pharmaceutical Products, the pharmaceutical manufacturing organization within ... Sciences and Materials Sciences company, and #1 on the ... in the category of "Product, Process and Green Innovations" ... Charlotte, North Carolina.DSM was considered based on its corporate ...
... 2011 With its governmental markets still depressed, Allied Healthcare Products ... second quarter of fiscal year 2011 and improvement in its year-over-year ... 31 was $117,000, or 1 cent per basic and diluted share, ... year,s quarter. For the first two quarters of the fiscal year, ...
Cached Medicine Technology:DSM Recognized With Profiles in Sustainability Award for Corporate Commitment to Sustainability and Innovations for Pharmaceutical Manufacturing 2DSM Recognized With Profiles in Sustainability Award for Corporate Commitment to Sustainability and Innovations for Pharmaceutical Manufacturing 3DSM Recognized With Profiles in Sustainability Award for Corporate Commitment to Sustainability and Innovations for Pharmaceutical Manufacturing 4Allied Healthcare Products Reports Modest Profit for Quarter 2Allied Healthcare Products Reports Modest Profit for Quarter 3Allied Healthcare Products Reports Modest Profit for Quarter 4
(Date:12/21/2014)... 2014 Recently, one of the best ... Prom Shop has introduced its new collection of ... big discounts on all its prom dresses &amp; other ... insists on providing top quality dress products and great ... considered as one of the best prom dresses online ...
(Date:12/21/2014)... Over the past 39 years, NES Health has ... departments across the nation, from quality of medical care ... an innovative suite of tools, systems, and programs that ... patient experience. , NES Health, a leading national ... for hospitals, announced the development and launch of its ...
(Date:12/21/2014)... CA (PRWEB) December 21, 2014 The Oncology ... drive in the Santa Ana and Whittier offices. The Hope ... brighten the lives of patients and their families during the ... reach out to approximately 70 children between both offices. This ... the help of Target’s community service team, store managers and ...
(Date:12/20/2014)... Weddingshe.com has recently announced its new collection of sweet ... occasion dresses for the coming new year. , ... for global women. Now, all the models on its ... off. Among the new items, the model of 10986064 ... very popular. What’s more, Weddingshe.com also provides a fast ...
(Date:12/20/2014)... holidays can be anything but joyous for people with ... and other allergy triggers. "The dust from the ... away in dank basements or dusty attics is triggering ... Shah, an affiliate faculty member at Loyola University Chicago ... Shah, who is also an allergist at Gottlieb ...
Breaking Medicine News(10 mins):Health News:New Prom Dresses From One Of The Best Prom Dresses Online Shops, LunaDress Prom Shop 2Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:Holiday Trimmings Can Trigger Allergies 2
... Hawaiians Access to Nursing Home, Assisted Living, Home Care and ... StatewideRICHMOND, Va., April 30 The cost of long term ... putting significant financial pressure on those in or near retirement, ... the same time, the current economic downturn has led to ...
... EPS (1) was $0.42 -- Annual Guidance Narrowed to $2.05 to $2.18 Adjusted Diluted EPS(1) - ... Inc. (NYSE: WST ) today announced its results for the first quarter of 2009. ... Three Months Ended, ... March 31, ...
... - Nuvo Research Inc. (TSX: NRI), a Canadian drug development ... that are delivered to and through the skin using its ... and operational results for the quarter ended March 31, 2009., ... Successfully completed all Pennsaid(R) studies necessary to resubmit, ...
... 2009 Performance Outlook -MELVILLE, N.Y., April 30 Gentiva Health ... of comprehensive home health services, today reported the following 2009 ... Net revenues of $288.9 ... $321.6 million, which included net revenues of $77.8 million from ...
... SUNNYVALE, Calif., April 30 Cepheid (Nasdaq: CPHD ) ... investor conferences, and invited investors to participate via webcast., ... York, NY, Wednesday, May 13, 2009 at 10.40 ... Boston, MA, Tuesday, May 19, 2009 at 8.50 ...
... ... ------- ... $4,150 $4,863 (15%), (Loss) / Income ... ($5.40) $0.56, Special Items ...
Cached Medicine News:Health News:Growth in Hawaii Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in Hawaii Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in Hawaii Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4Health News:West Announces First Quarter 2009 Results 2Health News:West Announces First Quarter 2009 Results 3Health News:West Announces First Quarter 2009 Results 4Health News:West Announces First Quarter 2009 Results 5Health News:West Announces First Quarter 2009 Results 6Health News:West Announces First Quarter 2009 Results 7Health News:West Announces First Quarter 2009 Results 8Health News:West Announces First Quarter 2009 Results 9Health News:West Announces First Quarter 2009 Results 10Health News:West Announces First Quarter 2009 Results 11Health News:West Announces First Quarter 2009 Results 12Health News:West Announces First Quarter 2009 Results 13Health News:West Announces First Quarter 2009 Results 14Health News:West Announces First Quarter 2009 Results 15Health News:West Announces First Quarter 2009 Results 16Health News:West Announces First Quarter 2009 Results 17Health News:West Announces First Quarter 2009 Results 18Health News:Nuvo announces 2009 first quarter financial results 2Health News:Nuvo announces 2009 first quarter financial results 3Health News:Nuvo announces 2009 first quarter financial results 4Health News:Nuvo announces 2009 first quarter financial results 5Health News:Nuvo announces 2009 first quarter financial results 6Health News:Nuvo announces 2009 first quarter financial results 7Health News:Nuvo announces 2009 first quarter financial results 8Health News:Nuvo announces 2009 first quarter financial results 9Health News:Nuvo announces 2009 first quarter financial results 10Health News:Nuvo announces 2009 first quarter financial results 11Health News:Gentiva Reports First Quarter 2009 Results 2Health News:Gentiva Reports First Quarter 2009 Results 3Health News:Gentiva Reports First Quarter 2009 Results 4Health News:Gentiva Reports First Quarter 2009 Results 5Health News:Gentiva Reports First Quarter 2009 Results 6
... Bone Cement consists of a ... containing bone cement liquid within ... sterile polyethylene bag,containing bone cement ... The interiors of the blister ...
Low viscosity bone cement without antibiotics for syringe use with an average setting time of approx. 7-9 Min., 40g of powder and 14.6g of liquid....
... represents new thinking to address common problems ... 5.85 mm diameter outer arthroscope sheath, the ... diameter Videoscope has superior access and mobility ... schoulder and especially in the elbow and ...
... enhance the llifestly of hypertensive and ... Coat Effect" normally associated with blood ... clinics. A user-friendly, one-step instrument, ... blood pressure monitoring from the comfort ...
Medicine Products: